Oramed Pharmaceuticals (ORMP) Liabilities and Shareholders Equity (2011 - 2026)

Oramed Pharmaceuticals (ORMP) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $268.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 82.22% year-over-year to $268.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $881.9 million (up 35.23% YoY) and the FY2025 annual result came in at $230.9 million, up 48.68% from the prior year.
• Liabilities and Shareholders Equity improved to $268.8 million in Q1 2026, from $230.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $268.8 million in Q1 2026 to a low of $147.5 million in Q1 2025.
• A 5-year average of $186.2 million and a median of $165.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity declined 29.6% — and 2026, when it jumped 82.22%.
• Tracing ORMP's Liabilities and Shareholders Equity over 5 years: stood at $161.6 million in 2022, then soared by 36.44% to $220.6 million in 2023, then dropped by 29.6% to $155.3 million in 2024, then soared by 48.68% to $230.9 million in 2025, then climbed by 16.45% to $268.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $268.8 million (Q1 2026), $230.9 million (Q4 2025), and $220.5 million (Q3 2025), per Business Quant data.